candesartan cilexetil has been researched along with Hypertension in 243 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated whether 10 mg per day of azilsartan, one-half of the normal dosage, would be non-inferior to 8 mg per day of candesartan cilexetil for controlling blood pressure in Japanese patients with hypertension." | 9.19 | Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. ( Arai, A; Kaneto, H; Katakami, N; Kusuda, Y; Matsuoka, TA; Shimomura, I; Shindo, M; Shiraiwa, T; Takahara, M, 2014) |
| "Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment." | 9.16 | Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. ( Enya, K; Ikeda, Y; Rakugi, H; Sugiura, K, 2012) |
| "In Korean adult patients with stage II hypertension, we evaluated the efficacy and tolerability of candesartan 16 mg/hydrochlorothiazide (HCT) 12." | 9.15 | Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. ( Ahn, YK; Choi, D; Chung, WJ; Hong, BK; Jeon, DW; Jung, HO; Kim, BO; Kim, D; Kim, SH; Lee, BK; Lee, HY; Lee, SH; Park, CK, 2011) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 9.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "This double-blind, randomised, controlled study compared the efficacy of candesartan cilexetil 8 mg (n = 87) and losartan 50 mg (n = 89), once daily for 6 weeks, relative to placebo (n = 80) in patients with mild-to-moderate essential hypertension (diastolic blood pressure (DBP): 95-115 mmHg)." | 9.12 | A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. ( Asmar, R; Baguet, JP; Mallion, JM; Mouret, S; Nisse-Durgeat, S, 2006) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 9.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "After screening and a single-blind, placebo run-in phase, ambulatory adult patients with mild to moderate hypertension (defined as a mean office sitting diastolic BP [DBP] and systolic BP [SBP], respectively, of 90-109 mm Hg and 140-179 mm Hg, and a mean ABPM DBP and SBP, respectively, of >or=80 mm Hg and >or=125 mm Hg) were randomised to once-daily treatment with imidapril or candesartan cilexetil for 12 weeks." | 9.12 | A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. ( Alegría, E; Gonzalez-Juanatey, JR; Marquez, E; Olivan, J; Palma-Gamiz, JL; Pêgo, M; Pujol, M; Sagastagoitia-Gorostiza, JD, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 9.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 9.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
| "The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-blind, placebo-controlled study." | 9.09 | Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Gradman, AH; Hardison, JD; Jones, DW; Levine, JH; Michelson, EL; Oparil, S; Prasad, R; Ripley, E; Zuschke, CA, 1999) |
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 9.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "This randomized, double-blind, placebo-controlled multicenter study was designed to evaluate the efficacy, tolerability, and safety of candesartan cilexetil in a diverse population of patients with severe systemic hypertension (diastolic blood pressure > or =110 mm Hg)." | 9.09 | Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. ( Oparil, S, 1999) |
| "The aim of this study was to evaluate the occurrence of dry cough during treatment with candesartan cilexetil, enalapril, or placebo in patients with hypertension and a history of angiotensin converting enzyme (ACE)-inhibitor-related cough." | 9.09 | Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. ( Campbell, LM; Carranza, J; Karrash, J; Tanser, PH; Toutouzas, P; Watts, R, 2000) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 9.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "After a 4-week placebo run-in period, 268 patients with mild-to-moderate hypertension were allocated randomly to groups to receive placebo, candesartan cilexetil (8 mg once daily) or losartan (50 mg once daily), for 4 weeks." | 9.09 | A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. ( Asmar, R; Lacourcière, Y, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 9.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| "To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension." | 9.09 | The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. ( Asmar, R; Hedner, T; Himmelmann, A; Keinänen-Kiukaanniemi, S; Redón, J; Wester, A, 2001) |
| "The long-term efficacy and tolerability of candesartan cilexetil was assessed in two open-label, prospective multicentre studies in patients with mild to moderate essential hypertension." | 9.08 | Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. ( Holzgreve, H; Sever, P, 1997) |
| "The objectives of this double-blind, multicenter, randomized, parallel-arm, placebo-controlled study were to evaluate the dose-related efficacy, tolerability, and safety of candesartan cilexetil, a potent, AT1 selective, long-acting angiotensin II receptor blocker, in 365 adult patients with systemic hypertension and mean sitting diastolic blood pressure (BP) of 95 to 114 mm Hg." | 9.08 | Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Edwards, DT; Fagan, TC; Flanagan, TL; Michelson, EL; Oparil, S; Reif, M; White, WB, 1998) |
| "Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension." | 9.08 | Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. ( Endoh, S; Inoue, S; Kinoshita, M; Maeda, K; Mitsunami, K; Okada, M; Sugihara, H; Takahashi, M, 1998) |
| "A Medline literature search was undertaken to identify randomised, controlled trials that examined the efficacy and cardiovascular outcomes associated with candesartan cilexetil in hypertension and chronic heart failure (CHF)." | 8.84 | Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. ( Meredith, PA, 2007) |
| "The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis focusing on major cardiovascular events and prospectively collected resource-use data from the CHARM-Added and CHARM-Alternative trials in patients with CHF and left ventricular (LV) systolic dysfunction." | 8.83 | Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. ( Keam, SJ; Plosker, GL, 2006) |
| "The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension." | 8.81 | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. ( Jarvis, B; Melian, EB, 2002) |
| "once daily candesartan cilexetil is effective and well tolerated when used once daily (as monotherapy or in combination with other antihypertensive agents) in patients with mild, moderate or severe hypertension." | 8.80 | Candesartan cilexetil. A review of its use in essential hypertension. ( Goa, KL; McClellan, KJ, 1998) |
| " The new angiotensin II type I (AT1) receptor blocker candesartan cilexetil has been shown to be effective in reducing target-organ damage in animal models of hypertension, even at doses that do not produce significant reductions in blood pressure." | 8.80 | Preserving target-organ function with candesartan cilexetil in patients with hypertension. ( Zannad, F, 2000) |
| "Patients on candesartan cilexetil had the highest incidence of neutropenia compared to those on other concomitant medications, including other ARBs." | 7.88 | Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia . ( Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M, 2018) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 7.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 7.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| "To investigate the relation between cardiovascular events and blood pressure or blood glucose control during long-term treatment with candesartan cilexetil in Japanese patients with hypertension and diabetes mellitus." | 7.75 | Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. ( Fujita, T; Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2009) |
| "Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life." | 7.74 | [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]. ( Fimmers, R; Mengden, T; Uen, S; Un, I; Vetter, H, 2007) |
| "Hypertension was well controlled by administration of candesartan cilexetil." | 7.72 | Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. ( Ishida, H; Omoto, K; Shimmura, H; Tanabe, K; Tokumoto, T; Toma, H, 2003) |
| "Candesartan cilexetil is an angiotensin II receptor antagonist that is widely used in the treatment of hypertension." | 7.72 | Erythema multiforme associated with candesartan cilexetil. ( Ejaz, AA; Walsh, JS; Wasiluk, A, 2004) |
| " The present study was undertaken to investigate the role of angiotensin II type I receptor (AT1 receptor) in hypertension-induced renal injury." | 7.69 | Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Kim, S; Miura, K; Ohta, K; Omura, T; Wada, T; Yukimura, T, 1994) |
| "We have previously demonstrated that captopril ameliorates glucose intolerance by partially preventing the reduction in postprandial skeletal muscle blood flow." | 7.69 | Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. ( Chen, S; Ishii, J; Kashiwabara, H; Katayama, S; Kosegawa, I, 1996) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 7.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 6.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| "The new guidelines for treatment of hypertension by the JNC VII in 2003 permit the initial use of a combination therapy, if blood pressure has to be lowered more than 20/10 mmHg." | 6.71 | Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. ( Bönner, G; Fuchs, W, 2004) |
| " In double-blind clinical trials in patients with primary hypertension, candesartan cilexetil 2-16 mg once-daily was associated with a low incidence of adverse events and drug-related withdrawals, similar to placebo." | 6.68 | Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. ( Belcher, G; Elmfeldt, D; George, M; Hübner, R; Lunde, H, 1997) |
| " From these model parameters, a cumulation half-life (t1/2, beta) of 29 h was derived." | 6.68 | Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ( Feltkamp, H; Gundert-Remy, U; Högemann, A; Meineke, I, 1997) |
| "Hypertension is one of the most prevalent disorders and the largest contributor to global mortality." | 6.48 | Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. ( Fujimoto, A; Kuwahara, K; Nakagawa, Y; Ueshima, K; Yasuno, S, 2012) |
| "Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist." | 6.43 | Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. ( Bönner, G; Fuchs, W, 2005) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 6.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| "The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession." | 6.41 | The role of angiotensin II receptor antagonists in hypertension management: focus on candesartan cilexetil. ( Grassi, G; Mancia, G, 2000) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 6.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| "We investigated whether 10 mg per day of azilsartan, one-half of the normal dosage, would be non-inferior to 8 mg per day of candesartan cilexetil for controlling blood pressure in Japanese patients with hypertension." | 5.19 | Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. ( Arai, A; Kaneto, H; Katakami, N; Kusuda, Y; Matsuoka, TA; Shimomura, I; Shindo, M; Shiraiwa, T; Takahara, M, 2014) |
| "DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension." | 5.19 | Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. ( Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014) |
| "Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment." | 5.16 | Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. ( Enya, K; Ikeda, Y; Rakugi, H; Sugiura, K, 2012) |
| "In Korean adult patients with stage II hypertension, we evaluated the efficacy and tolerability of candesartan 16 mg/hydrochlorothiazide (HCT) 12." | 5.15 | Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. ( Ahn, YK; Choi, D; Chung, WJ; Hong, BK; Jeon, DW; Jung, HO; Kim, BO; Kim, D; Kim, SH; Lee, BK; Lee, HY; Lee, SH; Park, CK, 2011) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 5.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "This double-blind, randomised, controlled study compared the efficacy of candesartan cilexetil 8 mg (n = 87) and losartan 50 mg (n = 89), once daily for 6 weeks, relative to placebo (n = 80) in patients with mild-to-moderate essential hypertension (diastolic blood pressure (DBP): 95-115 mmHg)." | 5.12 | A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. ( Asmar, R; Baguet, JP; Mallion, JM; Mouret, S; Nisse-Durgeat, S, 2006) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 5.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "This is an additional analysis of a previously reported randomised, double-blind study in which 635 patients with mainly mild to moderate hypertension were randomised to 8 weeks of treatment with either olmesartan medoxomil 20 mg/day or candesartan cilexetil 8 mg/day." | 5.12 | Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. ( Arakawa, K; Brunner, HR, 2006) |
| "After screening and a single-blind, placebo run-in phase, ambulatory adult patients with mild to moderate hypertension (defined as a mean office sitting diastolic BP [DBP] and systolic BP [SBP], respectively, of 90-109 mm Hg and 140-179 mm Hg, and a mean ABPM DBP and SBP, respectively, of >or=80 mm Hg and >or=125 mm Hg) were randomised to once-daily treatment with imidapril or candesartan cilexetil for 12 weeks." | 5.12 | A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. ( Alegría, E; Gonzalez-Juanatey, JR; Marquez, E; Olivan, J; Palma-Gamiz, JL; Pêgo, M; Pujol, M; Sagastagoitia-Gorostiza, JD, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 5.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "Seventy-four patients with mild hypertension were randomly assigned to a 7-day treatment period with either 16 mg candesartan cilexetil or placebo." | 5.11 | Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. ( Haastert, B; Hauner, H; Lee, YM; Nicuta-Rölfs, TO; Skurk, T; Wirth, A, 2004) |
| "These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 5.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
| "Candesartan cilexetil is a possible treatment for hypertension in renal allograft recipients." | 5.11 | Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. ( Birkel, M; Kiel, G; Philipp, T; Pietruck, F; Stahlheber-Dilg, B, 2005) |
| "The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-blind, placebo-controlled study." | 5.09 | Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Gradman, AH; Hardison, JD; Jones, DW; Levine, JH; Michelson, EL; Oparil, S; Prasad, R; Ripley, E; Zuschke, CA, 1999) |
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 5.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "This randomized, double-blind, placebo-controlled multicenter study was designed to evaluate the efficacy, tolerability, and safety of candesartan cilexetil in a diverse population of patients with severe systemic hypertension (diastolic blood pressure > or =110 mm Hg)." | 5.09 | Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. ( Oparil, S, 1999) |
| "The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multicentre, prospective, randomized, double-blind, parallel-group study designed to compare the effects of candesartan cilexetil and placebo in elderly patients with mild hypertension." | 5.09 | Study on COgnition and Prognosis in the Elderly (SCOPE). ( Bánki, CM; Baro, F; Breteler, M; Carbonin, PU; Castaigne, A; Correia, M; de Leeuw, PW; Degaute, JP; Elmfeldt, D; Engedal, K; Farsang, C; Ferro, J; Hachinski, V; Hansson, L; Hofman, A; James, OF; Krisin, E; Leeman, M; Leys, D; Lithell, H; Lobo, A; Nordby, G; Olofsson, B; Skoog, I; Zanchetti, A, 1999) |
| "The aim of this study was to evaluate the occurrence of dry cough during treatment with candesartan cilexetil, enalapril, or placebo in patients with hypertension and a history of angiotensin converting enzyme (ACE)-inhibitor-related cough." | 5.09 | Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. ( Campbell, LM; Carranza, J; Karrash, J; Tanser, PH; Toutouzas, P; Watts, R, 2000) |
| "This randomized, double-blind, placebo-controlled crossover study evaluated the effects of the angiotensin II type 1 (AT1)-receptor blocker candesartan cilexetil on renal blood perfusion and glomerular filtration in patients with primary hypertension with diastolic blood pressure of 100 to 114 mm Hg." | 5.09 | Candesartan cilexetil and renal hemodynamics in hypertensive patients. ( Andersson, OK; Friberg, P; Fridman, K; Wysocki, M, 2000) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 5.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "After a 4-week placebo run-in period, 268 patients with mild-to-moderate hypertension were allocated randomly to groups to receive placebo, candesartan cilexetil (8 mg once daily) or losartan (50 mg once daily), for 4 weeks." | 5.09 | A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. ( Asmar, R; Lacourcière, Y, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 5.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| "To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension." | 5.09 | The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. ( Asmar, R; Hedner, T; Himmelmann, A; Keinänen-Kiukaanniemi, S; Redón, J; Wester, A, 2001) |
| "258 men (mean age 57 +/- 11 years) and 316 women (58 +/- 12) with essential hypertension (blood pressure < 180/95 mm Hg) under ambulatory therapy with ACE-inhibitors, beta-blockers or calcium channel blockers with inadequate efficacy or tolerability were switched to monotherapy with candesartan cilexetil." | 5.09 | [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)]. ( Baumgart, P; Düsing, R; Pohlmeyer, H; Reismann, J, 2001) |
| "This study was designed to investigate the effects of angiotensin II (AII) receptor antagonist and angiotensin converting enzyme (ACE) inhibitor on insulin resistance, and the mechanism by which ACE inhibitor improves insulin-dependent glucose uptake (insulin sensitivity) in an insulin-resistant hypertensive rat model (fructose-fed rats, FFR) and in essential hypertensives (EHT)." | 5.08 | Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. ( Higashiura, K; Hirata, A; Iimura, O; Masuda, A; Matsuda, K; Miyazaki, Y; Nakagawa, M; Shimamoto, K; Takizawa, H; Ura, N, 1995) |
| "The long-term efficacy and tolerability of candesartan cilexetil was assessed in two open-label, prospective multicentre studies in patients with mild to moderate essential hypertension." | 5.08 | Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. ( Holzgreve, H; Sever, P, 1997) |
| "The objectives of this double-blind, multicenter, randomized, parallel-arm, placebo-controlled study were to evaluate the dose-related efficacy, tolerability, and safety of candesartan cilexetil, a potent, AT1 selective, long-acting angiotensin II receptor blocker, in 365 adult patients with systemic hypertension and mean sitting diastolic blood pressure (BP) of 95 to 114 mm Hg." | 5.08 | Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Edwards, DT; Fagan, TC; Flanagan, TL; Michelson, EL; Oparil, S; Reif, M; White, WB, 1998) |
| "This study was performed to assess the acute effects of the new angiotensin II antagonist, candesartan cilexetil, on systemic and renal haemodynamics in patients with sustained essential hypertension [diastolic blood pressure (DBP) 95-114 mmHg]." | 5.08 | Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. ( Andersson, OK; Friberg, P; Fridman, K; Sunzel, M; Wysocki, M, 1998) |
| "Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension." | 5.08 | Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. ( Endoh, S; Inoue, S; Kinoshita, M; Maeda, K; Mitsunami, K; Okada, M; Sugihara, H; Takahashi, M, 1998) |
| " To examine the role of the renin-angiotensin system in hypertension in the elderly, we evaluated the antihypertensive response to enalapril and to TCV-116, an angiotensin II type-1 receptor antagonist, in elderly patients with essential hypertension." | 5.07 | Role of the renin-angiotensin system in hypertension in the elderly. ( Higaki, J; Mikami, H; Nagano, M; Ogihara, T, 1994) |
| "The authors analyze the importance of the combination therapy of candesartan cilexetil plus hydrochlorothiazide in the treatment of hypertension." | 4.88 | Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. ( Mugellini, A; Nieswandt, V, 2012) |
| "This review focuses on the use of candesartan cilexetil in Phase II and Phase III trials and their implications for clinical usage in the treatment of arterial hypertension and heart failure." | 4.87 | Candesartan cilexetil: an update. ( Joost, A; Radke, PW; Schunkert, H, 2011) |
| "A Medline literature search was undertaken to identify randomised, controlled trials that examined the efficacy and cardiovascular outcomes associated with candesartan cilexetil in hypertension and chronic heart failure (CHF)." | 4.84 | Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. ( Meredith, PA, 2007) |
| "The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis focusing on major cardiovascular events and prospectively collected resource-use data from the CHARM-Added and CHARM-Alternative trials in patients with CHF and left ventricular (LV) systolic dysfunction." | 4.83 | Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. ( Keam, SJ; Plosker, GL, 2006) |
| "The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension." | 4.81 | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. ( Jarvis, B; Melian, EB, 2002) |
| "once daily candesartan cilexetil is effective and well tolerated when used once daily (as monotherapy or in combination with other antihypertensive agents) in patients with mild, moderate or severe hypertension." | 4.80 | Candesartan cilexetil. A review of its use in essential hypertension. ( Goa, KL; McClellan, KJ, 1998) |
| "Candesartan cilexetil has shown potent and long-lasting antihypertensive effects in clinical trials and in several animal models of hypertension." | 4.80 | Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action. ( Inada, Y; Kanagawa, R; Misumi, Y; Naka, T; Nishikawa, K; Ojima, M, 1999) |
| "All literature on the use of candesartan cilexetil for treating hypertension and congestive heart failure were included." | 4.80 | Candesartan cilexetil: an angiotensin II receptor blocker. ( Kaul, AF; McVoy, HJ; Stoukides, CA, 1999) |
| " The new angiotensin II type I (AT1) receptor blocker candesartan cilexetil has been shown to be effective in reducing target-organ damage in animal models of hypertension, even at doses that do not produce significant reductions in blood pressure." | 4.80 | Preserving target-organ function with candesartan cilexetil in patients with hypertension. ( Zannad, F, 2000) |
| "Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve haemodynamics in some patients with congestive heart failure." | 4.79 | Angiotensin II antagonists DuP 753 and TCV 116. ( Brunner, HR; Burnier, M; Delacrétaz, E; Nussberger, J; Waeber, B, 1994) |
| "In controlled, well designed, clinical trials involving more than 5000 subjects with mild to moderate hypertension, candesartan cilexetil at 4-8 mg was as effective as enalapril at 10-20 mg." | 4.79 | Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. ( Sever, PS, 1997) |
| "We investigated the effects of an angiotensin II type 1 (AT1)-receptor antagonist on experimental cardiac hypertrophy, vascular thickening and nephrosclerosis, in order to determine the involvement of this receptor in the development of cardiovascular and renal damage." | 4.79 | Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. ( Iwao, H; Kim, S, 1997) |
| "Patients on candesartan cilexetil had the highest incidence of neutropenia compared to those on other concomitant medications, including other ARBs." | 3.88 | Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia . ( Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M, 2018) |
| "Candesartan cilexetil is widely used in the management of hypertension and heart failure." | 3.85 | Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil. ( AboulFotouh, K; Allam, AA; El-Badry, M; El-Sayed, AM, 2017) |
| "Candesartan cilexetil (CC) is used in the treatment of hypertension and heart failure." | 3.83 | Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. ( Dudhipala, N; Veerabrahma, K, 2016) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 3.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| " Patients with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination of candesartan cilexetil 16 mg and HCTZ 12." | 3.77 | Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). ( Bönner, G; Bramlage, P; Landers, B, 2011) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 3.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| "To investigate the relation between cardiovascular events and blood pressure or blood glucose control during long-term treatment with candesartan cilexetil in Japanese patients with hypertension and diabetes mellitus." | 3.75 | Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. ( Fujita, T; Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2009) |
| "The angiotensin-receptor blocker candesartan cilexetil is a well-tolerated antihypertensive agent with demonstrated benefits in adults with hypertension." | 3.74 | Candesartan cilexetil effectively reduces blood pressure in hypertensive children. ( Franks, AM; Gardner, SF; O'Brien, CE; Stowe, CD; Wells, TG, 2008) |
| "Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life." | 3.74 | [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]. ( Fimmers, R; Mengden, T; Uen, S; Un, I; Vetter, H, 2007) |
| "Hypertension was well controlled by administration of candesartan cilexetil." | 3.72 | Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. ( Ishida, H; Omoto, K; Shimmura, H; Tanabe, K; Tokumoto, T; Toma, H, 2003) |
| "These studies determined the ability of AT1 receptor blockade or 'triple therapy', to reverse angiotensin II-induced hypertension and improve autoregulatory behavior." | 3.72 | Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. ( Cook, AK; Imig, JD; Inscho, EW; Murzynowski, JB, 2004) |
| "Candesartan cilexetil is an angiotensin II receptor antagonist that is widely used in the treatment of hypertension." | 3.72 | Erythema multiforme associated with candesartan cilexetil. ( Ejaz, AA; Walsh, JS; Wasiluk, A, 2004) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| " Candesartan cilexetil (TCV-116), a potent angiotensin II (AII) receptor antagonist, has beneficial effects on hypertension as well as on heart, renal and cerebrovascular disease." | 3.71 | The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. ( Nagisa, Y; Nakagawa, S; Shintani, A, 2001) |
| "Angiotensin II (Ang II) plays an important role as a modulator of vascular structure and function in arterial hypertension." | 3.71 | TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats. ( Kobayashi, N; Kobayashi, T; Matsuoka, H; Mori, Y; Nakano, S; Shirataki, H; Tsubokou, Y, 2001) |
| " Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated in patients with essential hypertension." | 3.70 | Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. ( Sever, PS, 1999) |
| "The aims were (1) to investigate the effect of hypertention on left ventricular dilatation and haemodynamic alterations following acute myocardial infarction in spontaneously hypertensive rats (SHR) and normotensive rats (WKY); (2) to compare haemodynamic indices between the two groups; (3) to assess whether the angiotensin II type 1 receptor antagonist (AIIA), TCV-116, prevented left ventricular dilatation after myocardial infarction; and (4) to compare the effect of AIIA with that of the angiotensin converting enzyme (ACE) inhibitor, delapril." | 3.69 | An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. ( Nishikimi, T; Takeda, T; Takeuchi, K; Yamagishi, H, 1995) |
| "To study the effects of blockade of the renin-angiotensin system on the development of hypertension and end-organ damage in hyporeninaemic deoxycorticosterone acetate (DOCA)-salt hypertensive rats, using an angiotensin II (Ang II) receptor antagonist (TCV-116) or an angiotensin converting enzyme (ACE) inhibitor (enalapril)." | 3.69 | Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. ( Inada, Y; Ishimura, Y; Kanagawa, R; Nishikawa, K; Wada, T, 1995) |
| " The present study was undertaken to investigate the role of angiotensin II type I receptor (AT1 receptor) in hypertension-induced renal injury." | 3.69 | Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Kim, S; Miura, K; Ohta, K; Omura, T; Wada, T; Yukimura, T, 1994) |
| "Recently, it has been suggested that angiotensin II (AII) might be associated with cardiac hypertrophy and fibrosis." | 3.69 | Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. ( Dohi, K; Iwano, M; Kagoshima, T; Konishi, N; Masuda, J; Nakamura, Y; Sakaguchi, Y; Sutani, T; Tsuchihashi, M; Tsuruta, S, 1994) |
| "To investigate the role of angiotensin II (Ang II) in hypertension-induced tissue injury, we gave TCV-116 (1 mg/kg per day PO), a nonpeptide Ang II type I receptor antagonist, or enalapril (10 mg/kg per day PO) to deoxycorticosterone acetate (DOCA)-salt hypertensive rats for 3 weeks and examined the effects on tissue mRNA levels for transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix components." | 3.69 | Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Kim, S; Miura, K; Ohta, K; Omura, T; Wada, T; Yukimura, T, 1994) |
| "Previously, we reported that an orally active angiotensin II (Ang II) receptor antagonist Losartan induces regression of left ventricular hypertrophy with reduction in the tissue Ang II contents in spontaneously hypertensive rats (SHR)." | 3.69 | TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. ( Fukuchi, S; Katoh, K; Mizuno, K; Niimura, S, 1994) |
| "To investigate the role of the renin-angiotensin system (RAS) on nephrosclerosis in salt-loaded, partially nephrectomized spontaneously hypertensive rats (SHR), we evaluated the effects of angiotensin II (ANGII) blockade on the progression of nephrosclerosis with an angiotensin type 1 receptor (AT1rec) antagonist [TCV-116 (TCV)] and an angiotensin-converting enzyme (ACE) inhibitor (enalapril) at the doses equivalent in reducing systemic blood pressure (BP)." | 3.69 | Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. ( Ikenaga, H; Kanno, Y; Okada, H; Saruta, T; Suzuki, H, 1995) |
| "We have previously demonstrated that captopril ameliorates glucose intolerance by partially preventing the reduction in postprandial skeletal muscle blood flow." | 3.69 | Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. ( Chen, S; Ishii, J; Kashiwabara, H; Katayama, S; Kosegawa, I, 1996) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 3.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| " A trend to dose-response relationship was observed in each subgroup." | 2.82 | Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. ( Cha, G; Kjeldsen, SE; Mancia, G; Villa, G, 2016) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 2.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| "Hypertension is a risk factor for the two leading causes of death in renal transplant recipients: cardiovascular disease (CVD) and graft failure." | 2.75 | Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. ( Geiger, H; Heemann, U; Legendre, C; Lièvre, M; Martinez, F; Moulin, B; Mourad, G; Philipp, T; Schmieder, R, 2010) |
| " Candesartan was generally well tolerated; two patients withdrew for adverse events (fatigue and worsening glomerulopathy)." | 2.75 | Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. ( Bagdasorova, IV; Drozdz, D; Gimpel, C; Hainer, JW; Montini, G; Schaefer, F; Sorof, J; Sugg, J; Teng, R; van de Walle, J; van Hoeck, K; Zurowska, A, 2010) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| " Eight candesartan patients discontinued treatment because of an adverse event." | 2.73 | Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. ( Hainer, JW; Radcliffe, J; Sorof, JM; Sugg, J; Teng, R; Trachtman, H, 2008) |
| "We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension." | 2.72 | Feasibility of treating prehypertension with an angiotensin-receptor blocker. ( Black, HR; Egan, BM; Grimm, RH; Julius, S; Kaciroti, N; Messerli, FH; Michelson, EL; Nesbitt, SD; Oparil, S; Schork, MA; Weber, MA, 2006) |
| "Arterial hypertension is involved in the pathogenesis of end organ damage by influencing the ability of the vascular endothelium to produce nitric oxide (NO)." | 2.72 | Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension. ( Delles, C; Harazny, J; Michelson, G; Oehmer, S; Schmieder, RE; Wärntges, S, 2006) |
| "Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study." | 2.71 | Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003) |
| "The candesartan cilexetil-treated patients exhibited improvement of several aspects of QOL, including general symptoms, physical symptoms and well-being, work and satisfaction and sleep scale." | 2.71 | The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients. ( Fujimoto, H; Kawashima, T; Koide, S; Kunitake, T; Yamamoto, S, 2003) |
| "Treatment with candesartan cilexetil restored a normal pattern of reactivity in retinal capillaries (l-NMMA: decrease in perfusion by 10%+/-17%, P<0." | 2.71 | Impaired endothelial function of the retinal vasculature in hypertensive patients. ( Delles, C; Harazny, J; Hilgers, KF; Michelson, G; Oehmer, S; Schmieder, RE, 2004) |
| "The new guidelines for treatment of hypertension by the JNC VII in 2003 permit the initial use of a combination therapy, if blood pressure has to be lowered more than 20/10 mmHg." | 2.71 | Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. ( Bönner, G; Fuchs, W, 2004) |
| "Hypertension is twice as common in postmenopausal than in premenopausal women." | 2.70 | Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. ( Abellán, J; de Castro, SS; De Vinuesa, SG; Fernández-Vega, F; Luño, J; Maceira, B; Nicolás, RR; Rodríguez, JC; Vegazo, O, 2002) |
| " In both treatment groups the dosage could be doubled after > or =2 weeks [according to blood pressure (BP) response] and, if necessary, subsequently decreased if the higher dosage was poorly tolerated." | 2.70 | Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. ( Forsén, B; Neldam, S, 2001) |
| "Candesartan cilexetil was similarly well tolerated as placebo." | 2.69 | The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. ( Andersson, OK; Neldam, S, 1998) |
| "Candesartan is an angiotensin II subtype 1 (AT1) receptor antagonist that is administered orally as candesartan cilexetil which is converted in the active compound." | 2.69 | Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. ( Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999) |
| "The purpose of this double-blind, forced titration study was to compare the antihypertensive effect duration of candesartan cilexetil, which has a longlasting binding to the human AT1-receptor, to that of losartan on ambulatory BP (ABP) not only during the 24-h dosing interval but also during the day of a missed dose intake." | 2.69 | A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo ( Asmar, R; Lacourcière, Y, 1999) |
| "To compare candesartan cilexetil and lisinopril in fixed combination with hydrochlorothiazide with respect to antihypertensive efficacy and tolerability." | 2.69 | Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. ( Istad, H; Keinänen-Kiukaanniemi, S; McInnes, GT; O'Kane, KP; Van Mierlo, HF, 2000) |
| " In double-blind clinical trials in patients with primary hypertension, candesartan cilexetil 2-16 mg once-daily was associated with a low incidence of adverse events and drug-related withdrawals, similar to placebo." | 2.68 | Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. ( Belcher, G; Elmfeldt, D; George, M; Hübner, R; Lunde, H, 1997) |
| " From these model parameters, a cumulation half-life (t1/2, beta) of 29 h was derived." | 2.68 | Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. ( Feltkamp, H; Gundert-Remy, U; Högemann, A; Meineke, I, 1997) |
| "Hypertension is one of the most prevalent disorders and the largest contributor to global mortality." | 2.48 | Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. ( Fujimoto, A; Kuwahara, K; Nakagawa, Y; Ueshima, K; Yasuno, S, 2012) |
| "It was launched in 1998 for the treatment of hypertension." | 2.45 | Candesartan: widening indications for this angiotensin II receptor blocker? ( Mendis, B; Page, SR, 2009) |
| " All of these were similar in design: i) a 4-week placebo run-in period, ii) a 4- to 6-week period (V1) with CC 8 mg once daily (od), after which the dosage was doubled if BP was not normalized (BP > 140/90 or BP >130/80 mmHg in diabetes), and iii) a 4- to 6-week period (V2) with CC 8 or 16 mg od." | 2.44 | Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. ( Asmar, R; Féghali, RE; Nisse-Durgeat, S, 2007) |
| " Depending on the BP response, dosage of CC 8 mg was doubled at the follow-up visit if BP >or=140/90 mmHg." | 2.44 | [Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes]. ( Asmar, R; El Féghali, R; Nisse-Durgeat, S, 2007) |
| "Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist." | 2.43 | Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. ( Bönner, G; Fuchs, W, 2005) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 2.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| "Candesartan cilexetil is an angiotensin receptor blocker with insurmountable binding properties to the angiotensin-1 receptor, long duration of action and improved efficacy." | 2.42 | Candesartan cilexetil in cardiovascular disease. ( Papademetriou, V; Ross, A, 2004) |
| " Each drug effectively lowers blood pressure during once daily administration to patients with mild to moderate hypertension, with candesartan cilexetil requiring the lowest dosage and providing dose-dependent efficacy." | 2.41 | Newly emerging pharmacologic differences in angiotensin II receptor blockers. ( Oparil, S, 2000) |
| "Candesartan cilexetil is an effective antihypertensive agent that can be used alone or in combination with other antihypertensive drugs." | 2.41 | Candesartan cilexetil: an angiotensin II-receptor blocker. ( See, S; Stirling, AL, 2000) |
| "Candesartan cilexetil has been found to produce a predictable and pronounced dose-dependent decrease in blood pressure, with placebo-like tolerability even at the highest doses studied." | 2.41 | Improving antihypertensive efficacy while maintaining placebo-like tolerability. ( Sever, PS, 2000) |
| " The trough-to-peak ratio is a useful measure of the persistence of antihypertensive efficacy at the end of the dosing interval." | 2.41 | Achieving quality 24-h blood pressure control with candesartan cilexetil. ( Meredith, P, 2000) |
| "Candesartan cilexetil has also been shown to be effective and well tolerated in combination with hydrochlorothiazide in those hypertensive patients who require more than one agent to reach their target blood pressure." | 2.41 | Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade. ( Ruilope, L, 2000) |
| "The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession." | 2.41 | The role of angiotensin II receptor antagonists in hypertension management: focus on candesartan cilexetil. ( Grassi, G; Mancia, G, 2000) |
| "Candesartan cilexetil is a potent and long-acting blocker that, when given once a day to patients, provides effective 24 hr blood pressure control." | 2.41 | [Angiotensin II receptor antagonists: candesartan cilexetil]. ( Furukawa, Y; Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 2000) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 2.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| " The usual maintenance doses of candesartan cilexetil are expected to be 8 mg and 16 mg once-daily and dosage adjustment does not appear to be necessary in elderly patients or those with mild to moderate renal or hepatic impairment." | 2.40 | Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. ( Sever, P, 1997) |
| "The main goal of the treatment of hypertension is to decrease cardiovascular morbidity and mortality." | 2.40 | Clinical efficacy of a new AT1 blocker. ( Heemann, U; Philipp, T, 1998) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| "Therefore, for the treatment of hypertension it is important to understand the mechanism of cardiac hypertrophy and to establish effective pharmaceutical interventions." | 2.40 | Role of the renin-angiotensin system in cardiac hypertrophy. ( Komuro, I; Yamazaki, T; Yazaki, Y, 1999) |
| "Candesartan cilexetil-treated banded rat hearts displayed shorter QT intervals and lower vulnerability to atrial and ventricular tachyarrhythmias than vehicle-treated banded hearts." | 1.72 | Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. ( Chang, GJ; Chen, WJ; Ko, YS; Lai, YJ; Lee, YS; Yeh, YH, 2022) |
| "Essential hypertension is a chronic pathology that causes long-term complications due to late diagnosis of patients, the inability to control the disease through medication, or due to the complexity of associated risk factors." | 1.43 | Evaluation of patients diagnosed with essential arterial hypertension through network analysis. ( Buda, V; Cristescu, C; Suciu, L; Tomescu, MC; Topîrceanu, A; Udrescu, L; Udrescu, M, 2016) |
| " These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2." | 1.36 | Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. ( Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010) |
| "To elucidate the pathogenesis of cerebral aneurysms, we focused on the contribution of endothelial damage in rats." | 1.35 | Endothelial damage due to impaired nitric oxide bioavailability triggers cerebral aneurysm formation in female rats. ( Jamous, MA; Kitazato, KT; Nagahiro, S; Tada, Y; Tamura, T; Uno, M; Yagi, K, 2009) |
| "The pregnancy was terminated, and she delivered at 27 weeks' gestation." | 1.35 | Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected. ( Hirahara, F; Ishikawa, H; Kato, K; Okuda, M; Takahashi, T, 2008) |
| " Combining candesartan-cilexetil with ramipril increased SBP reduction synergistically rather than additively, since the dose-response curve was shifted 6." | 1.32 | Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. ( Dominiak, P; Gieselberg, A; Jöhren, O; Raasch, W; Schwartz, S, 2004) |
| " Oral dosing of L-NAME (100 mg/kg per day) for 7 days significantly raised plasma fibrinogen concentration in rats." | 1.31 | Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats. ( Fujimura, A; Sugimoto, K; Tsuruoka, S, 2001) |
| " For the effects of AT1 receptor blockade, the AT1 receptor antagonist, TCV-116, was orally administered at a dosage of 0." | 1.31 | Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. ( Ito, H; Suzuki, T; Takemori, K, 2001) |
| "In order to investigate the role of Angiotensin II (AII) for the vasogenic cerebral edema, the AT1 receptor antagonist (TCV-116) was administered to 19-week-old stroke-prone spontaneously hypertensive rats (SHRSP) for 2 weeks at a dosage which did not decrease the blood pressure." | 1.31 | AT1 receptor antagonist prevents brain edema without lowering blood pressure. ( Ito, H; Kawai, J; Suzuki, T; Takemori, K, 2000) |
| "Cardiac hypertrophy was reduced by all three treatments, but to a lesser extent by hydralazine (treatment study), and this regression of cardiac hypertrophy persisted only with both types of RAS inhibition (withdrawal study)." | 1.31 | Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. ( Paull, JR; Widdop, RE, 2001) |
| " In addition, endothelium-dependent and endothelium-independent relaxation was evaluated by dose-response curves to acetylcholine (in the presence or absence of a bradykinin-receptor blocker and of indomethacin) and sodium nitroprusside." | 1.30 | Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. ( Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D; Rosei, EA, 1998) |
| "DOCA-salt hypertension was induced in 8-wk-old male Wistar rats by uninephrectomy and administration of DOCA (25 mg every fourth day, subcutaneously) and 1% NaCl in the drinking water for 4 wk." | 1.30 | Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. ( Brown, L; Duce, B; Miric, G; Sernia, C, 1999) |
| "The pharmacokinetic profile of candesartan cilexetil might be altered in patients with end-stage renal disease (ESRD)." | 1.30 | Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. ( Frey, FJ; Pfister, M; Schaedeli, F; Uehlinger, DE, 1999) |
| "Furthermore, TCV-116 regressed cardiac hypertrophy and lessened the medial hypertrophy of the aorta in SHRSP." | 1.29 | Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Iwao, H; Kim, S; Miura, K; Ohta, K; Omura, T; Yukimura, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 87 (35.80) | 18.2507 |
| 2000's | 121 (49.79) | 29.6817 |
| 2010's | 34 (13.99) | 24.3611 |
| 2020's | 1 (0.41) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, B | 1 |
| Schieffer, B | 1 |
| Chang, GJ | 1 |
| Yeh, YH | 1 |
| Chen, WJ | 1 |
| Ko, YS | 1 |
| Lai, YJ | 1 |
| Lee, YS | 1 |
| AboulFotouh, K | 1 |
| Allam, AA | 1 |
| El-Badry, M | 1 |
| El-Sayed, AM | 1 |
| Katsube, Y | 1 |
| Hira, D | 1 |
| Tsujimoto, M | 1 |
| Koide, H | 1 |
| Minegaki, T | 1 |
| Ikeda, Y | 2 |
| Morita, SY | 1 |
| Nishiguchi, K | 1 |
| Terada, T | 1 |
| Kishi, T | 1 |
| Hirooka, Y | 1 |
| Sunagawa, K | 1 |
| Nishida, Y | 2 |
| Takahashi, Y | 2 |
| Susa, N | 2 |
| Kanou, N | 1 |
| Nakayama, T | 2 |
| Asai, S | 2 |
| Takahara, M | 1 |
| Shiraiwa, T | 1 |
| Shindo, M | 1 |
| Arai, A | 1 |
| Kusuda, Y | 1 |
| Katakami, N | 1 |
| Kaneto, H | 1 |
| Matsuoka, TA | 1 |
| Shimomura, I | 1 |
| Dudhipala, N | 1 |
| Veerabrahma, K | 1 |
| Miura, S | 1 |
| Saku, K | 1 |
| Kjeldsen, SE | 3 |
| Sica, D | 1 |
| Haller, H | 1 |
| Cha, G | 2 |
| Gil-Extremera, B | 1 |
| Harvey, P | 1 |
| Heyvaert, F | 1 |
| Lewin, AJ | 1 |
| Villa, G | 2 |
| Mancia, G | 4 |
| Suciu, L | 1 |
| Cristescu, C | 1 |
| Topîrceanu, A | 1 |
| Udrescu, L | 1 |
| Udrescu, M | 1 |
| Buda, V | 1 |
| Tomescu, MC | 1 |
| Yada, Y | 1 |
| Wang, Z | 1 |
| Niu, Q | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Liu, K | 1 |
| Liu, Y | 1 |
| Liu, J | 1 |
| Jin, F | 1 |
| Li, X | 1 |
| Wei, Y | 1 |
| Dzongowski, P | 1 |
| Li, N | 1 |
| Wang, L | 1 |
| Radlmaier, A | 1 |
| Sunami, E | 1 |
| Nomura, K | 1 |
| Nishiyama, Y | 1 |
| Katayama, Y | 1 |
| Franks, AM | 1 |
| O'Brien, CE | 1 |
| Stowe, CD | 1 |
| Wells, TG | 1 |
| Gardner, SF | 1 |
| Trachtman, H | 1 |
| Hainer, JW | 2 |
| Sugg, J | 2 |
| Teng, R | 2 |
| Sorof, JM | 1 |
| Radcliffe, J | 1 |
| Kawamori, R | 1 |
| Fujita, T | 1 |
| Matsuoka, H | 5 |
| Umemura, S | 1 |
| Saito, Y | 1 |
| Furukawa, T | 1 |
| Hatsuno, T | 1 |
| Ueno, Y | 1 |
| Nagaoka, K | 1 |
| Watari, Y | 1 |
| Yamakawa, T | 1 |
| Sagawa, T | 1 |
| Isshiki, T | 1 |
| Tamura, T | 1 |
| Jamous, MA | 1 |
| Kitazato, KT | 1 |
| Yagi, K | 1 |
| Tada, Y | 1 |
| Uno, M | 1 |
| Nagahiro, S | 1 |
| Edes, I | 1 |
| Baguet, JP | 2 |
| Asmar, R | 8 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 5 |
| Mallion, JM | 3 |
| Mendis, B | 1 |
| Page, SR | 1 |
| Lee, R | 1 |
| Schulz, EG | 1 |
| Bahri, S | 1 |
| Schettler, V | 1 |
| Popov, AF | 1 |
| Hermann, M | 1 |
| Kusumoto, K | 1 |
| Mori, M | 1 |
| Tanokashira, J | 1 |
| Totsuka, N | 3 |
| Philipp, T | 4 |
| Martinez, F | 1 |
| Geiger, H | 1 |
| Moulin, B | 1 |
| Mourad, G | 1 |
| Schmieder, R | 1 |
| Lièvre, M | 1 |
| Heemann, U | 2 |
| Legendre, C | 1 |
| Lopau, K | 1 |
| Wanner, C | 1 |
| Mengden, T | 2 |
| Uen, S | 2 |
| Bramlage, P | 4 |
| Schaefer, F | 1 |
| van de Walle, J | 1 |
| Zurowska, A | 1 |
| Gimpel, C | 1 |
| van Hoeck, K | 1 |
| Drozdz, D | 1 |
| Montini, G | 1 |
| Bagdasorova, IV | 1 |
| Sorof, J | 1 |
| Weiss, J | 1 |
| Sauer, A | 1 |
| Divac, N | 1 |
| Herzog, M | 1 |
| Schwedhelm, E | 1 |
| Böger, RH | 1 |
| Haefeli, WE | 1 |
| Benndorf, RA | 1 |
| Ketelhut, R | 1 |
| Hoy, SM | 2 |
| Keating, GM | 2 |
| Bönner, G | 3 |
| Landers, B | 1 |
| Joost, A | 1 |
| Schunkert, H | 2 |
| Radke, PW | 1 |
| Lee, HY | 1 |
| Hong, BK | 1 |
| Chung, WJ | 1 |
| Lee, BK | 1 |
| Lee, SH | 1 |
| Jeon, DW | 1 |
| Ahn, YK | 1 |
| Kim, D | 1 |
| Park, CK | 1 |
| Kim, SH | 1 |
| Jung, HO | 1 |
| Kim, BO | 1 |
| Choi, D | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Tanahashi, N | 1 |
| Nakagawara, J | 1 |
| Okada, Y | 1 |
| Minematsu, K | 1 |
| Kaku, K | 1 |
| Enya, K | 2 |
| Sugiura, K | 2 |
| Riem, L | 1 |
| Rakugi, H | 3 |
| Ogihara, T | 7 |
| Miyata, Y | 1 |
| Sasai, K | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 2 |
| Mifune, H | 1 |
| Yasuno, S | 1 |
| Fujimoto, A | 1 |
| Nakagawa, Y | 1 |
| Kuwahara, K | 1 |
| Ueshima, K | 1 |
| Mugellini, A | 2 |
| Nieswandt, V | 1 |
| Nakaya, H | 2 |
| Sasamura, H | 4 |
| Mifune, M | 1 |
| Shimizu-Hirota, R | 1 |
| Kuroda, M | 1 |
| Hayashi, M | 2 |
| Saruta, T | 6 |
| Skov, K | 1 |
| Julius, S | 2 |
| Nesbitt, S | 1 |
| Mulvany, MJ | 1 |
| Nagisa, Y | 2 |
| Shintani, A | 2 |
| Nakagawa, S | 2 |
| Fernández-Vega, F | 1 |
| Abellán, J | 1 |
| Vegazo, O | 1 |
| De Vinuesa, SG | 1 |
| Rodríguez, JC | 1 |
| Maceira, B | 1 |
| de Castro, SS | 1 |
| Nicolás, RR | 1 |
| Luño, J | 1 |
| Isobe, N | 1 |
| Taniguchi, K | 1 |
| Oshima, S | 1 |
| Ono, Z | 1 |
| Adachi, H | 1 |
| Toyama, T | 1 |
| Naito, S | 1 |
| Hoshizaki, H | 1 |
| Kamiyama, H | 1 |
| O'Brien, JT | 1 |
| Wiseman, R | 1 |
| Burton, EJ | 1 |
| Barber, B | 1 |
| Wesnes, K | 1 |
| Saxby, B | 1 |
| Ford, GA | 1 |
| Andersen, NH | 1 |
| Knudsen, ST | 1 |
| Poulsen, PL | 1 |
| Poulsen, SH | 1 |
| Helleberg, K | 1 |
| Eiskjaer, H | 1 |
| Hansen, KW | 1 |
| Bek, T | 1 |
| Mogensen, CE | 1 |
| Murayama, S | 1 |
| Hirano, T | 1 |
| Sakaue, T | 1 |
| Okada, K | 1 |
| Ikejiri, R | 1 |
| Adachi, M | 1 |
| Sakata, Y | 4 |
| Yamamoto, K | 4 |
| Mano, T | 4 |
| Nishikawa, N | 4 |
| Yoshida, J | 3 |
| Nakayama, H | 1 |
| Otsu, K | 1 |
| Suzuki, K | 2 |
| Tada, M | 1 |
| Hori, M | 4 |
| Miwa, T | 4 |
| Masuyama, T | 4 |
| Omoto, K | 1 |
| Tanabe, K | 1 |
| Tokumoto, T | 1 |
| Shimmura, H | 1 |
| Ishida, H | 1 |
| Toma, H | 1 |
| Skurk, T | 1 |
| Lee, YM | 1 |
| Nicuta-Rölfs, TO | 1 |
| Haastert, B | 1 |
| Wirth, A | 1 |
| Hauner, H | 1 |
| Yamamoto, S | 1 |
| Kawashima, T | 1 |
| Kunitake, T | 1 |
| Koide, S | 1 |
| Fujimoto, H | 1 |
| Delles, C | 2 |
| Michelson, G | 2 |
| Harazny, J | 2 |
| Oehmer, S | 2 |
| Hilgers, KF | 1 |
| Schmieder, RE | 2 |
| Raasch, W | 1 |
| Jöhren, O | 1 |
| Schwartz, S | 1 |
| Gieselberg, A | 1 |
| Dominiak, P | 1 |
| Inscho, EW | 2 |
| Cook, AK | 2 |
| Murzynowski, JB | 1 |
| Imig, JD | 2 |
| Fuchs, W | 2 |
| Ostergren, J | 1 |
| Ejaz, AA | 1 |
| Walsh, JS | 1 |
| Wasiluk, A | 1 |
| Willemsen, JM | 1 |
| Rabelink, TJ | 1 |
| Boer, P | 1 |
| Gaillard, CA | 1 |
| Ross, A | 1 |
| Papademetriou, V | 1 |
| Porcellati, C | 1 |
| Dusing, R | 2 |
| Nishio, M | 1 |
| Ohtani, T | 1 |
| Rosei, EA | 3 |
| Rizzoni, D | 3 |
| Muiesan, ML | 3 |
| Sleiman, I | 2 |
| Salvetti, M | 2 |
| Monteduro, C | 1 |
| Porteri, E | 3 |
| Hasebe, N | 1 |
| Kikuchi, K | 1 |
| Imbs, JL | 1 |
| De Ciuceis, C | 1 |
| Rodella, L | 1 |
| Rezzani, R | 1 |
| Paiardi, S | 1 |
| Bianchi, R | 1 |
| Ruggeri, G | 1 |
| Boari, GE | 1 |
| Zani, F | 1 |
| Miclini, M | 1 |
| Rahman, M | 2 |
| Morita, S | 1 |
| Fukui, T | 2 |
| Sakamoto, J | 1 |
| Pietruck, F | 1 |
| Kiel, G | 1 |
| Birkel, M | 1 |
| Stahlheber-Dilg, B | 1 |
| Naruse, M | 3 |
| Tanabe, A | 3 |
| Hara, Y | 1 |
| Takagi, S | 2 |
| Imaki, T | 2 |
| Takano, K | 2 |
| Nakamura, H | 1 |
| Inoue, T | 1 |
| Arakawa, N | 1 |
| Shimizu, Y | 1 |
| Yoshigae, Y | 1 |
| Fujimori, I | 1 |
| Shimakawa, E | 1 |
| Toyoshi, T | 1 |
| Yokoyama, T | 1 |
| Weisser, B | 1 |
| Gerwe, M | 1 |
| Braun, M | 1 |
| Funken, C | 2 |
| Nesbitt, SD | 2 |
| Egan, BM | 1 |
| Weber, MA | 2 |
| Michelson, EL | 7 |
| Kaciroti, N | 1 |
| Black, HR | 1 |
| Grimm, RH | 1 |
| Messerli, FH | 1 |
| Oparil, S | 5 |
| Schork, MA | 1 |
| Wärntges, S | 1 |
| Mouret, S | 1 |
| Simonetti, GD | 1 |
| von Vigier, RO | 1 |
| Konrad, M | 1 |
| Rizzi, M | 1 |
| Fossali, E | 1 |
| Bianchetti, MG | 1 |
| Kitamura, Y | 1 |
| Nakamura, M | 1 |
| Ryuzaki, M | 1 |
| Sasaki, H | 1 |
| Kanai, S | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Yamamura, S | 1 |
| Shirai, K | 1 |
| Grassi, DG | 1 |
| Conen, D | 1 |
| Martina, B | 1 |
| Baumann, M | 1 |
| van den Born, BJ | 1 |
| Lopez-Plasencia, Y | 1 |
| Amela-Peris, R | 1 |
| Garcia-Delgado, Y | 1 |
| Ikeda, J | 1 |
| Yao, K | 1 |
| Matsubara, M | 1 |
| Plosker, GL | 1 |
| Keam, SJ | 1 |
| Brunner, HR | 2 |
| Arakawa, K | 3 |
| Un, I | 1 |
| Fimmers, R | 1 |
| Vetter, H | 1 |
| Mann, J | 1 |
| Ishiguro, K | 1 |
| Sakamaki, Y | 1 |
| Itoh, H | 4 |
| Palma-Gamiz, JL | 1 |
| Pêgo, M | 1 |
| Marquez, E | 1 |
| Pujol, M | 1 |
| Olivan, J | 1 |
| Alegría, E | 1 |
| Sagastagoitia-Gorostiza, JD | 1 |
| Gonzalez-Juanatey, JR | 1 |
| Mitsuyama, S | 1 |
| Féghali, RE | 1 |
| Meredith, PA | 1 |
| Fogari, R | 1 |
| Derosa, G | 1 |
| El Féghali, R | 1 |
| Schönrock, E | 1 |
| Odoj, P | 1 |
| Wolf, WP | 1 |
| Kato, K | 1 |
| Okuda, M | 1 |
| Ishikawa, H | 1 |
| Takahashi, T | 1 |
| Hirahara, F | 1 |
| Mori, T | 1 |
| Nishimura, H | 1 |
| Ueyama, M | 1 |
| Kubota, J | 1 |
| Kawamura, K | 1 |
| Iimura, O | 2 |
| Shimamoto, K | 1 |
| Matsuda, K | 1 |
| Masuda, A | 1 |
| Takizawa, H | 1 |
| Higashiura, K | 1 |
| Miyazaki, Y | 1 |
| Hirata, A | 1 |
| Ura, N | 1 |
| Nakagawa, M | 4 |
| Nishikimi, T | 1 |
| Yamagishi, H | 1 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Kim, S | 4 |
| Ohta, K | 4 |
| Hamaguchi, A | 3 |
| Omura, T | 3 |
| Yukimura, T | 3 |
| Miura, K | 3 |
| Inada, Y | 10 |
| Ishimura, Y | 5 |
| Chatani, F | 3 |
| Iwao, H | 2 |
| Wada, T | 7 |
| Kanagawa, R | 4 |
| Nishikawa, K | 7 |
| Delacrétaz, E | 1 |
| Nussberger, J | 1 |
| Burnier, M | 1 |
| Waeber, B | 1 |
| Jover, B | 1 |
| Mimran, A | 1 |
| Abe, K | 1 |
| Ishii, M | 3 |
| Hiwada, K | 1 |
| Fujishima, M | 3 |
| Fukiyama, K | 1 |
| Kawabata, M | 1 |
| Takabatake, T | 1 |
| Ohta, H | 1 |
| Nakamura, S | 1 |
| Hara, H | 1 |
| Takakuwa, H | 1 |
| Han, WH | 1 |
| Kobayashi, K | 1 |
| Ashino, K | 1 |
| Gotoh, E | 2 |
| Sumita, S | 1 |
| Takasaki, I | 2 |
| Sugimoto, K | 3 |
| Shionoiri, H | 2 |
| Nagano, M | 1 |
| Higaki, J | 2 |
| Mikami, H | 2 |
| Kino, H | 1 |
| Hama, J | 1 |
| Takenaka, T | 1 |
| Sugimura, K | 1 |
| Kamoi, K | 1 |
| Shimada, S | 1 |
| Yamamoto, Y | 1 |
| Nagata, S | 1 |
| Horiuchi, M | 1 |
| Katori, R | 1 |
| Shibouta, Y | 3 |
| Ojima, M | 5 |
| Kubo, K | 2 |
| Naka, T | 3 |
| Kagoshima, T | 1 |
| Masuda, J | 1 |
| Sutani, T | 1 |
| Sakaguchi, Y | 1 |
| Tsuchihashi, M | 1 |
| Tsuruta, S | 1 |
| Iwano, M | 1 |
| Dohi, K | 1 |
| Nakamura, Y | 1 |
| Konishi, N | 1 |
| Takeda, K | 3 |
| Fujita, H | 3 |
| Nakamura, K | 2 |
| Uchida, A | 3 |
| Tanaka, M | 2 |
| Nakata, T | 3 |
| Sasaki, S | 3 |
| Sanada, T | 3 |
| Noda, M | 2 |
| Shiojima, I | 1 |
| Yamazaki, T | 2 |
| Komuro, I | 2 |
| Zou, Z | 1 |
| Wang, Y | 1 |
| Mizuno, T | 1 |
| Ueki, K | 1 |
| Tobe, K | 1 |
| Kadowaki, T | 1 |
| Mizuno, K | 2 |
| Niimura, S | 2 |
| Katoh, K | 1 |
| Fukuchi, S | 2 |
| Kohara, K | 1 |
| Okuda, N | 1 |
| Okada, H | 1 |
| Suzuki, H | 1 |
| Kanno, Y | 1 |
| Ikenaga, H | 1 |
| Yoshimoto, T | 1 |
| Naruse, K | 1 |
| Shionoya, K | 1 |
| Hagiwara, H | 1 |
| Hirose, S | 1 |
| Muraki, T | 1 |
| Demura, H | 1 |
| Ebina, T | 1 |
| Iwamoto, T | 1 |
| Takizawa, T | 1 |
| Chen, S | 1 |
| Kashiwabara, H | 2 |
| Kosegawa, I | 1 |
| Ishii, J | 2 |
| Katayama, S | 2 |
| Takenaka, K | 1 |
| Inaba, M | 1 |
| Itabashi, A | 1 |
| Fujisawa, Y | 1 |
| Ménard, J | 1 |
| Chatellier, G | 1 |
| Azizi, M | 2 |
| Fridman, K | 3 |
| Andersson, OK | 6 |
| Wysocki, M | 4 |
| Friberg, P | 3 |
| Heuer, HJ | 1 |
| Schöndorfer, G | 1 |
| Högemann, AM | 1 |
| Zanchetti, A | 3 |
| Omboni, S | 2 |
| Di Biagio, C | 1 |
| Franke, H | 1 |
| Neldam, S | 4 |
| Plouin, PF | 1 |
| Letzel, H | 1 |
| Arens, HJ | 1 |
| Sever, P | 2 |
| Holzgreve, H | 1 |
| McInnes, GT | 2 |
| O'Kane, KP | 2 |
| Jonker, J | 1 |
| Roth, J | 1 |
| Trenkwalder, P | 5 |
| Lehtovirta, M | 2 |
| Dahl, K | 2 |
| Belcher, G | 1 |
| Hübner, R | 1 |
| George, M | 1 |
| Elmfeldt, D | 2 |
| Lunde, H | 1 |
| Obayashi, M | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Kobayashi, S | 1 |
| Tanigawa, T | 1 |
| Hironaka, K | 1 |
| Ryouke, T | 1 |
| Matsuzaki, M | 1 |
| Katoh, T | 1 |
| Kurokawa, K | 1 |
| Takuwa, Y | 1 |
| Obata, J | 1 |
| Nakamura, T | 1 |
| Kuroyanagi, R | 1 |
| Yoshida, Y | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Miki, S | 1 |
| Morimoto, S | 1 |
| Kawa, T | 1 |
| Meineke, I | 1 |
| Feltkamp, H | 1 |
| Högemann, A | 1 |
| Gundert-Remy, U | 1 |
| Sever, PS | 4 |
| Bunt, T | 1 |
| Dumaswala, A | 1 |
| Mulder, H | 1 |
| Anderson, OK | 1 |
| Reif, M | 1 |
| White, WB | 2 |
| Fagan, TC | 1 |
| Flanagan, TL | 2 |
| Edwards, DT | 1 |
| Cushing, DJ | 3 |
| Bettoni, G | 1 |
| Piccoli, A | 1 |
| Castellano, M | 1 |
| Pasini, G | 1 |
| Guelfi, D | 1 |
| McClellan, KJ | 1 |
| Goa, KL | 1 |
| Sunzel, M | 1 |
| Brown, L | 1 |
| Duce, B | 1 |
| Miric, G | 1 |
| Sernia, C | 1 |
| Deichmann, PC | 1 |
| Morsing, P | 1 |
| Mitsunami, K | 1 |
| Inoue, S | 1 |
| Maeda, K | 1 |
| Endoh, S | 1 |
| Takahashi, M | 2 |
| Okada, M | 1 |
| Sugihara, H | 1 |
| Kinoshita, M | 1 |
| Bell, TP | 1 |
| DeQuattro, V | 1 |
| Lasseter, KC | 1 |
| Ruff, D | 1 |
| Hardison, JD | 2 |
| Cushing, D | 1 |
| Kezer, AE | 1 |
| Chung, O | 1 |
| Csikós, T | 1 |
| Unger, T | 3 |
| Misumi, Y | 1 |
| Buter, H | 1 |
| Navis, GY | 1 |
| Woittiez, AJ | 1 |
| de Zeeuw, D | 1 |
| de Jong, PE | 1 |
| Zuschke, CA | 2 |
| Keys, I | 1 |
| Munger, MA | 1 |
| Carr, AA | 1 |
| Marinides, GN | 1 |
| Hayes, JL | 1 |
| Xie, Z | 1 |
| Gao, M | 1 |
| Togashi, H | 1 |
| Saito, H | 1 |
| Koyama, T | 1 |
| Pfister, M | 1 |
| Schaedeli, F | 1 |
| Frey, FJ | 1 |
| Uehlinger, DE | 1 |
| Tsuchihashi, T | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Abe, I | 2 |
| Levine, JH | 1 |
| Gradman, AH | 1 |
| Ripley, E | 1 |
| Jones, DW | 1 |
| Prasad, R | 2 |
| Otsuka, F | 1 |
| Ogura, T | 1 |
| Yamauchi, T | 1 |
| Sato, M | 1 |
| Kataoka, H | 1 |
| Kageyama, J | 1 |
| Makino, H | 1 |
| Dell'Oro, R | 1 |
| Turri, C | 1 |
| Grassi, G | 2 |
| Hansson, L | 1 |
| Lithell, H | 1 |
| Skoog, I | 1 |
| Baro, F | 1 |
| Bánki, CM | 1 |
| Breteler, M | 1 |
| Carbonin, PU | 1 |
| Castaigne, A | 1 |
| Correia, M | 1 |
| Degaute, JP | 1 |
| Engedal, K | 1 |
| Farsang, C | 1 |
| Ferro, J | 1 |
| Hachinski, V | 1 |
| Hofman, A | 1 |
| James, OF | 1 |
| Krisin, E | 1 |
| Leeman, M | 1 |
| de Leeuw, PW | 1 |
| Leys, D | 1 |
| Lobo, A | 1 |
| Nordby, G | 1 |
| Olofsson, B | 1 |
| Lacourcière, Y | 2 |
| Stoukides, CA | 1 |
| McVoy, HJ | 1 |
| Kaul, AF | 1 |
| Gavras, H | 1 |
| Fridman, KU | 1 |
| Friberg, PR | 1 |
| Tanser, PH | 1 |
| Campbell, LM | 1 |
| Carranza, J | 1 |
| Karrash, J | 1 |
| Toutouzas, P | 1 |
| Watts, R | 1 |
| Yazaki, Y | 1 |
| Higashi, T | 1 |
| Kobayashi, N | 4 |
| Hara, K | 3 |
| Shirataki, H | 2 |
| See, S | 1 |
| Stirling, AL | 1 |
| Istad, H | 1 |
| Keinänen-Kiukaanniemi, S | 2 |
| Van Mierlo, HF | 1 |
| Malmqvist, K | 1 |
| Kahan, T | 1 |
| Dahl, M | 1 |
| Kondo, H | 1 |
| Akehi, N | 1 |
| Kuzuya, T | 1 |
| MacGregor, GA | 1 |
| Viskoper, JR | 1 |
| Antonios, TF | 1 |
| He, FJ | 1 |
| Goto, K | 1 |
| Fujii, K | 1 |
| Onaka, U | 1 |
| Ohma, KP | 1 |
| Milon, H | 1 |
| Valnes, K | 1 |
| Meredith, P | 1 |
| Ruilope, L | 1 |
| Zannad, F | 1 |
| Belz, GG | 1 |
| Badguet, JP | 1 |
| Tepel, M | 1 |
| van der Giet, M | 1 |
| Zidek, W | 1 |
| Furukawa, Y | 1 |
| Nakano, S | 2 |
| Mori, Y | 2 |
| Tsubokou, Y | 3 |
| Tsuruoka, S | 1 |
| Fujimura, A | 1 |
| Kloner, RA | 1 |
| Weinberger, M | 1 |
| Pool, JL | 1 |
| Chrysant, SG | 1 |
| Harris, SM | 1 |
| Zyczynski, TM | 1 |
| Leidy, NK | 1 |
| Forsén, B | 1 |
| Ito, H | 2 |
| Takemori, K | 2 |
| Suzuki, T | 2 |
| Himmelmann, A | 1 |
| Wester, A | 1 |
| Redón, J | 1 |
| Hedner, T | 1 |
| Watanabe, S | 1 |
| Campbell, M | 1 |
| Sonkodi, S | 1 |
| Soucek, M | 1 |
| Wiecek, A | 1 |
| Johansen, TL | 1 |
| Kjaer, A | 1 |
| Baumgart, P | 1 |
| Reismann, J | 1 |
| Pohlmeyer, H | 1 |
| Kawai, J | 1 |
| Vidt, DG | 1 |
| Ridley, E | 1 |
| Harris, S | 1 |
| Vendetti, J | 1 |
| Wang, R | 1 |
| Paull, JR | 1 |
| Widdop, RE | 1 |
| Christensen, PK | 1 |
| Lund, S | 1 |
| Parving, HH | 1 |
| Kobayashi, T | 1 |
| Chang, CL | 1 |
| Melian, EB | 1 |
| Jarvis, B | 2 |
| Easthope, SE | 1 |
| Sugawara, M | 1 |
| Yamaguchi, Y | 1 |
| Ookawara, T | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Tani, M | 1 |
| Saito, I | 1 |
| Sanada, H | 1 |
| Okazaki, K | 1 |
| Yamaguchi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension[NCT01303783] | Phase 2 | 1,381 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period.[NCT00244621] | Phase 3 | 95 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 m[NCT00621153] | Phase 4 | 214 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)[NCT00227318] | Phase 3 | 1,000 participants | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | -11.1 |
| Atacand .20 mg | -40.6 |
| Atacand .40 mg | -50.0 |
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | 0.0 |
| Atacand .20 mg | -29.2 |
| Atacand .40 mg | 0.0 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -5.2 |
| Atacand .20 mg | -7.9 |
| Atacand .40 mg | -11.1 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -6.0 |
| Atacand .20 mg | -8.9 |
| Atacand .40 mg | -12.0 |
Mean of the changed DBP from baseline after 4 weeks (NCT00621153)
Timeframe: 4 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Candesartan Cilexetil/Hydroclorozide Combination Therapy | -17.0 |
| Candesartan Cilexetil Monotherapy | -14.1 |
52 reviews available for candesartan cilexetil and Hypertension
| Article | Year |
|---|---|
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 2003 |
Candesartan: widening indications for this angiotensin II receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
[Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trial | 2009 |
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2009 |
Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphen | 2010 |
Candesartan cilexetil: an update.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Clinical Trials, Phase | 2011 |
Candesartan in the treatment of hypertension: what have we learnt in the last decade?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clini | 2011 |
Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 2012 |
Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2012 |
[Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2002 |
Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; Drug Therapy, C | 2003 |
Candesartan for the treatment of hypertension and heart failure.
Topics: Administration, Oral; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; Dr | 2004 |
Candesartan cilexetil in cardiovascular disease.
Topics: Adult; Aged; Benzimidazoles; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; D | 2004 |
Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 2005 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Cost o | 2006 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cli | 2007 |
Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl | 2007 |
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
[Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; | 2007 |
Angiotensin II antagonists DuP 753 and TCV 116.
Topics: Administration, Oral; Angiotensin II; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Respo | 1994 |
Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1994 |
[Angiotensin receptor antagonist for therapy of patients with hypertension].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 1997 |
Do we need angiotensin II antagonists to treat hypertensive patients?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Humans | 1997 |
Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug | 1997 |
Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bip | 1997 |
Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1997 |
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1997 |
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1998 |
Candesartan cilexetil. A review of its use in essential hypertension.
Topics: Aged; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Te | 1998 |
Clinical efficacy of a new AT1 blocker.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Angiotensin II receptor pharmacology and AT1-receptor blockers.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 1999 |
Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Topics: Administration, Oral; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 1999 |
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimida | 1999 |
Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Bip | 1999 |
Candesartan cilexetil: an angiotensin II receptor blocker.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2000 |
Update on the clinical pharmacology of candesartan cilexetil.
Topics: Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Prodrugs; Randomized Controlled Trials as | 2000 |
Role of the renin-angiotensin system in cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
Candesartan cilexetil: an angiotensin II-receptor blocker.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2000 |
Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clini | 2000 |
Achieving quality 24-h blood pressure control with candesartan cilexetil.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 2000 |
Efficacy and tolerability of candesartan cilexetil in special patient groups.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart | 2000 |
Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug | 2000 |
Preserving target-organ function with candesartan cilexetil in patients with hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2000 |
The role of angiotensin II receptor antagonists in hypertension management: focus on candesartan cilexetil.
Topics: Adult; Age Factors; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2000 |
Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
[Angiotensin II receptor antagonists: candesartan cilexetil].
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as To | 2000 |
Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diure | 2002 |
Candesartan cilexetil: an update of its use in essential hypertension.
Topics: Adsorption; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |
88 trials available for candesartan cilexetil and Hypertension
| Article | Year |
|---|---|
Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studie | 2014 |
Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Press | 2014 |
Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Ch | 2016 |
Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Therapy, Com | 2016 |
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.
Topics: Adolescent; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Child; Doub | 2008 |
Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2009 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2010 |
Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood Pressu | 2011 |
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complica | 2011 |
Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.
Topics: Adolescent; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Child; Child, Preschool; Do | 2012 |
Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian People; Benzimidazoles; Biphe | 2012 |
Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; | 2012 |
Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Denmark; Hemodynamics; | 2002 |
Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2002 |
Cognitive associations of subcortical white matter lesions in older people.
Topics: Aged; Antihypertensive Agents; Basal Ganglia; Benzimidazoles; Biphenyl Compounds; Brain; Cognition; | 2002 |
Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; Drug Therapy, C | 2003 |
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Anthropometry; Antihypertensive Agents; Benzimidazoles; Bip | 2004 |
The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 2003 |
Impaired endothelial function of the retinal vasculature in hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Flow Veloc | 2004 |
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, | 2004 |
Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2004 |
Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Data Interpretation, St | 2004 |
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2005 |
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Bi | 2005 |
Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bl | 2005 |
Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arte | 2005 |
Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Benzimidazoles; Biological Availability; Biphe | 2005 |
[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2005 |
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2006 |
A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil | 2006 |
Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type | 2006 |
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2006 |
A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2007 |
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; | 2007 |
Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Open clinical studies on a new angiotensin II receptor antagonist, TCV 116.
Topics: Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Administration Schedule; Heart Rate; Humans | 1994 |
Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Bloo | 1994 |
Effect of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1994 |
Role of the renin-angiotensin system in hypertension in the elderly.
Topics: Adult; Aged; Aging; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzi | 1994 |
Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1997 |
Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1997 |
A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 1997 |
Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1997 |
Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Doubl | 1997 |
Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1997 |
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 1998 |
Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Apolipoproteins; Benzimidazo | 1998 |
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1998 |
Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Topics: Acute-Phase Reaction; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Ben | 1998 |
Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group.
Topics: Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Me | 1998 |
Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1998 |
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relations | 1999 |
Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bi | 1999 |
Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Bli | 1999 |
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 1999 |
Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive A | 1999 |
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Demography; Double-Blind Method; | 1999 |
Study on COgnition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1999 |
A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 1999 |
Candesartan cilexetil in hypertension: effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Baroreflex; Benzimidazoles; | 1999 |
Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2000 |
Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2000 |
Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Candesartan cilexetil and renal hemodynamics in hypertensive patients.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2000 |
Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.
Topics: Aldosterone; Amlodipine; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2000 |
Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 2000 |
Reducing cardiovascular morbidity and mortality in the elderly.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 2000 |
A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2000 |
Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2001 |
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Cha | 2001 |
Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2001 |
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2001 |
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weigh | 2001 |
[Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Losartan; | 2001 |
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2001 |
Discordant responses to two classes of drugs acting on the renin-angiotensin system.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2001 |
104 other studies available for candesartan cilexetil and Hypertension
| Article | Year |
|---|---|
Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Biphenyl Compounds; Calcium; Hyper | 2022 |
Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimida | 2017 |
Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineopl | 2018 |
Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Hea | 2014 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mel | 2013 |
Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ben | 2016 |
Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Male; Oxa | 2014 |
Evaluation of patients diagnosed with essential arterial hypertension through network analysis.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Essential | 2016 |
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Azetid | 2016 |
Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Gene E | 2016 |
Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Arginine; Benzimidazoles; Biomarkers; | 2016 |
Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Press | 2008 |
Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood G | 2009 |
Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; B | 2009 |
Endothelial damage due to impaired nitric oxide bioavailability triggers cerebral aneurysm formation in female rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Benzimidazoles; Bip | 2009 |
Ask the doctor. After being diagnosed with high blood pressure several years ago, I started taking diltiazem and Atacand. The results were good, giving me an average blood pressure of 110/65. I recently developed gastroenteritis and aspiration pneumoni
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2009 |
Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Hu | 2009 |
Hypertension after kidney transplantation: still a SECRET?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Creatin | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfa | 2010 |
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2011 |
Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
[EFFECTIVE data. New effectiveness dimensions in antihypertensive combination therapy].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topi | 2011 |
[Focus on compliance. Rapid goal attainment in hypertension].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relations | 2011 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Base Sequence; Benzimidazoles; B | 2002 |
[A megatrial of ARB in Japan--CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2002 |
Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |
Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2003 |
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2004 |
Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2004 |
Erythema multiforme associated with candesartan cilexetil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2005 |
Physicians' attitudes towards and reasons for participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Antihypertensive Agents; Attitude of Health Personnel; Benzimidazoles; Biphenyl Compounds; Humans; H | 2005 |
Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ben | 2004 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compoun | 2005 |
Pharmacotherapy for prehypertension--mission accomplished?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2006 |
Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphen | 2006 |
Treating prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
Treating prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
Treating prehypertension.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Treating prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; | 2006 |
[Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure De | 2007 |
[Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2007 |
Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
Topics: Aging; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles | 2007 |
Perspectives on prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Topics: Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Drug Combinations | 2008 |
Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetic Nephrop | 2008 |
Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomyopath | 1995 |
Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Biphenyl Compounds | 1995 |
Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Bip | 1995 |
Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Enala | 1994 |
Angiotensin II Receptor Antagonists: Can they Go Beyond ACE Inhibitors? Proceedings of a satellite symposium to the 15th scientific meeting of the International Society of Hypertension. Melbourne, Australia, March 1994.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimidazoles | 1994 |
Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1994 |
Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin III; Ang | 1994 |
Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Collagen; Desoxycorticosterone; Enalapr | 1994 |
Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Hydra | 1994 |
TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihyperten | 1994 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1995 |
Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calci | 1996 |
AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1996 |
Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1995 |
Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Topics: Administration, Oral; Adrenal Glands; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 1997 |
A case of renin-producing juxtaglomerular tumor: effect of ACE inhibitor or angiotensin II receptor antagonist.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1997 |
Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Angiote | 1997 |
Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Femal | 1997 |
Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 1997 |
Increased expression of parathyroid hormone-related peptide gene in blood vessels of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood V | 1997 |
Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; | 1997 |
Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1997 |
Candesartan vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Confounding Factors, Epidemiologic; Hum | 1998 |
Candesartan cilexetil vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Randomi | 1998 |
Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimida | 1998 |
Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |
Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 1999 |
Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1999 |
Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1999 |
Chronic treatment with angiotensin II type 1 receptor antagonist suppresses glomerular activator protein-1 activity in salt-sensitive hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Bo | 2000 |
Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
Topics: Angiotensin Receptor Antagonists; Animals; Aspartic Acid Endopeptidases; Benzimidazoles; Biphenyl Co | 2000 |
Renin-angiotensin system blockade improves endothelial dysfunction in hypertension.
Topics: Acetylcholine; Administration, Oral; Angiotensin Receptor Antagonists; Animals; Anti-Inflammatory Ag | 2000 |
Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Tolerance; F | 2001 |
Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2001 |
Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Disease Models | 2001 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.
Topics: Acute Kidney Injury; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2001 |
AT1 receptor antagonist prevents brain edema without lowering blood pressure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood | 2001 |
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2001 |
TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Biphenyl Comp | 2001 |
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; | 2002 |
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2002 |
Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1992 |